CD274 and neoplasm: The OS was tested hierarchically in the PD-L1-high group (≥50% of tumor cells [TC], or ≥ 10% of ICs), the combined PD-L1-high and PD-L1-intermediate group (≥5% of TC or IC), and, at last, in the whole intention-to-treat (ITT) WT population.